secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0000950170-25-019854
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q4 revenue $165M, FY $560M; guides 2025 revenue $640-670M
--------------------------------------------------------------------

- Q4 2024 total revenue $165M (+29% YoY); FY 2024 total revenue $560M (+29% YoY).
- Crysvita FY revenue $410M (+25% YoY); Dojolvi FY revenue $88M (+25% YoY).
- FY 2024 net loss $569M ($6.29/diluted share) vs $607M ($8.25) in 2023; cash used ops $414M.
- 2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M; lower cash ops expected.
- PDUFA decision for UX111 gene therapy (Sanfilippo syndrome) expected H2 2025; BLA filing for DTX401 (GSDIa) mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/0000950170-25-019854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-20250213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-019854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer